Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

December 1, 2022

https://www.globenewswire.com/news-release/2022/12/01/2565830/0/en/Cognition-Therapeutics-Presents-Scientific-Rationale-Clinical-Biomarker-and-Preclinical-Data-supporting-a-Phase-2-Clinical-Trial-with-CT1812-in-Geographic-Atrophy-Secondary-to-Dry-.html

PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (Nasdaq:CGTX), (the “Company” or “Cognition”) today announced that the scientific rationale, supporting proof-of-concept data and design of the planned Phase 2 trial of CT1812 in geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) will be communicated in an oral presentation at the 2022 Dry AMD Therapeutic Development Summit. Age-related macular degeneration is the leading cause of irreversible central vision loss in the world, with dry AMD affecting an estimated 10 million people in the U.S., 1.5 million of whom have advanced disease or GA.

Read more at globenewswire.com

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.